Aimmune Therapeutics Inc (NASDAQ:AIMT) major shareholder Bakker Juliet Tammenoms acquired 9,375 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $32.00 per share, for a total transaction of $300,000.00. Following the completion of the transaction, the insider now owns 16,651 shares in the company, valued at approximately $532,832. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) opened at $33.00 on Wednesday. Aimmune Therapeutics Inc has a 12-month low of $15.97 and a 12-month high of $42.00.
Several institutional investors and hedge funds have recently modified their holdings of AIMT. First Republic Investment Management Inc. bought a new stake in shares of Aimmune Therapeutics in the 4th quarter worth approximately $202,000. SG Americas Securities LLC raised its holdings in Aimmune Therapeutics by 54.7% in the 3rd quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 2,979 shares during the last quarter. Virtu Financial LLC purchased a new position in Aimmune Therapeutics in the 4th quarter worth approximately $239,000. Daiwa SB Investments Ltd. raised its holdings in Aimmune Therapeutics by 44.5% in the 4th quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 2,245 shares during the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in Aimmune Therapeutics in the 4th quarter worth approximately $282,000. 62.04% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Aimmune Therapeutics Inc (NASDAQ:AIMT) Major Shareholder Buys $300,000.00 in Stock” was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://weekherald.com/2018/03/14/aimmune-therapeutics-inc-aimt-major-shareholder-bakker-juliet-tammenoms-acquires-9375-shares.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.